Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029933 · ClinicalTrials.gov registry record
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
A clinical trial of Influenza and Community-acquired Pneumonia, sponsored by Kaiser Permanente.
- Recruiting
- Registry status
- 960,000
- Enrollment target
- 1
- Study location
NCT06029933: Recruiting study of Influenza and Community-acquired Pneumonia, sponsored by Kaiser Permanente.
NCT06029933 is a study of Influenza and Community-acquired Pneumonia that is actively recruiting participants, run by Kaiser Permanente. The registered enrollment target is 960,000 participants, above the 30,650-participant average among 156 other Influenza trials with a reported enrollment target (3032% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06029933, a study of Influenza and Community-acquired Pneumonia, is actively recruiting participants, sponsored by Kaiser Permanente.
- RECRUITING
- Registry status
- 960,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24 and 2024/25 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
Primary Outcome
KPNC members ≥65 years who receive Fluad or Fluzone High-Dose will be retrospectively assessed for the presence of PCR-confirmed influenza. This outcome will be assessed in single-season analyses (2023/24, 2024/25, and 2026/27 separately) and a pooled analysis across all seasons.
Conditions Studied
Interventions
- BIOLOGICAL Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
- BIOLOGICAL High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Study Locations (1)
California
- Kaiser Permanente Northern California (entire region) - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960,000 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2026-05 |
What NCT06029933 shows while recruiting
NCT06029933 is an observational study that tracks outcomes without assigning an intervention. Its 960,000 participants enrollment target places it among the larger protocols in the corpus, above the 30,650-participant average among 156 other Influenza trials with a reported enrollment target (3032% higher).
The record links to 3 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4) is the first listed.
NCT06029933 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06029933 about?
NCT06029933 is a clinical study titled "Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years". This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adult...
What is the current status of trial NCT06029933?
This trial is currently recruiting. The enrollment target is 960,000 participants. The study started on 2023-08-17. Estimated completion is 2026-05.
What conditions does trial NCT06029933 study?
This clinical trial studies the following conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events.
What interventions are being tested in trial NCT06029933?
The interventions under investigation include: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4) (BIOLOGICAL), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06029933?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06029933 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06029933's enrollment target sits among peer trials
960,000 2nd of 156 the highest of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Influenza Immunization in Adults Over Age 75
RECRUITING · NA
-
H5N1 Milk Detection Study
RECRUITING · NA
-
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
- NCT07224685 · 1,000,000 participants
A Study of Mayo Clinic CV Research Heart & Voice Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI